Inhibition of methicillin-resistant Staphylococcus aureus colonization of oral cavities in newborns by viridans group

Related Experiment Video

Updated: Oct 8, 2026

A Murine Model of Group B Streptococcus Vaginal Colonization
10:19

A Murine Model of Group B Streptococcus Vaginal Colonization

Published on: November 16, 2016

Y Uehara1, K Kikuchi, T Nakamura

  • 1Division of Clinical Pathology, Nagano Children's Hospital, Toyoshina, Japan. ue3527@jeans.ocn.ne.jp

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|April 24, 2001
PubMed

Insights

Viridans group streptococci colonization significantly reduced methicillin-resistant Staphylococcus aureus (MRSA) acquisition in newborns. This suggests a protective role for these bacteria against MRSA colonization in neonatal intensive care units.

Area of Science:

  • Microbiology
  • Neonatalogy
  • Infectious Diseases

Background:

  • Neonatal intensive care units (NICUs) are high-risk environments for healthcare-associated infections.
  • Methicillin-resistant Staphylococcus aureus (MRSA) is a significant pathogen causing infections in vulnerable neonates.
  • Understanding colonization dynamics is crucial for preventing MRSA transmission in NICUs.

Purpose of the Study:

  • To investigate the potential protective effect of viridans group streptococci (VGS) colonization against MRSA colonization in newborns.
  • To determine if VGS presence influences MRSA acquisition rates in a neonatal intensive care unit setting.

Main Methods:

  • A retrospective cohort study comparing MRSA colonization rates in newborns with and without VGS colonization.
  • Patient data collected over a 26-month period at a children's hospital.
  • Comparison of MRSA colonization prevalence between two groups of newborns matched for hospitalization duration.

Main Results:

  • Overall MRSA colonization rate was 49.9% among 415 newborns by discharge.
  • Newborns colonized with VGS (Group 2, n=63) had a significantly lower MRSA colonization rate (9.5%) compared to those without VGS (Group 1, n=103) (44.7%).
  • No significant differences in patient characteristics (birth weight, diseases) were noted between the groups.

Conclusions:

  • Viridans group streptococci colonization appears to inhibit subsequent colonization by MRSA in newborns.
  • VGS may play a protective role in preventing MRSA colonization in the neonatal intensive care unit setting.
  • Early colonization with commensal bacteria like VGS could be a strategy to prevent pathogen colonization.

More Related Videos

Deferred Growth Inhibition Assay to Quantify the Effect of Bacteria-derived Antimicrobials on Competition07:42

Deferred Growth Inhibition Assay to Quantify the Effect of Bacteria-derived Antimicrobials on Competition

Published on: September 3, 2016

Related Concept Videos

Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Surface Membrane Barriers01:18

Surface Membrane Barriers

The skin and mucous membranes serve as the primary line of defense against pathogens by providing both physical and chemical protection. These barriers are essential in preventing the entry and establishment of microbes, thereby maintaining the integrity of the host.
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
The Oral Microbiota01:27

The Oral Microbiota

The oral microbiome includes a complex ecosystem comprising over 700 microbial species, identified through genomic sequencing and culture-based analyses to date. This community includes a core microbiome, found universally among individuals, and a variable component influenced by environmental factors such as diet, lifestyle, and host genetics. Site-specific conditions, including oxygen gradients, pH levels, and nutrient availability, determine the spatial distribution of these microorganisms...
Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...